Synonyms: ETX-2514 | EXT2514 | Xacduro® (sulbactam and durlobactam)
durlobactam is an approved drug (FDA (2023))
Compound class:
Synthetic organic
Comment: Durlobactam (ETX2514) is a broad-spectrum diazabicyclooctanone (DBO) class non-beta-lactam beta-lactamase inhibitor [1]. It reduces beta-lactamase-mediated degradation of beta-lactam antibacterials, and has been demonstrated to restore sulbactam activity against Acinetobacter species, including contemporary multidrug-resistant strains [4]. There is evidence that a few carbapenem- and colistin-resistant, metallo beta-lactamase (MBL)-producing strains of A. baumannii are resistant to sulbactam/durlobactam dual therapy [2,5].
|
|
References |
1. Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, Lahiri S, Shapiro AB, McLeod SM, Carter NM et al.. (2017)
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol, 2: 17104. [PMID:28665414] |
2. Findlay J, Poirel L, Bouvier M, Nordmann P. (2022)
In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance. J Glob Antimicrob Resist, 30: 445-450. [PMID:35618210] |
3. Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L et al.. (2023)
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis, 23 (9): 1072-1084. [PMID:37182534] |
4. Papp-Wallace KM, McLeod SM, Miller AA. (2023)
Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species. Clin Infect Dis, 76 (Supplement_2): S194-S201. [PMID:37125470] |
5. Principe L, Di Bella S, Conti J, Perilli M, Piccirilli A, Mussini C, Decorti G. (2022)
Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review. Antibiotics (Basel), 11 (12). DOI: 10.3390/antibiotics11121793 [PMID:36551450] |